Verified

Evolving Treatment Options in First-Line Metastatic Urothelial Carcinoma (mUC) and Muscle Invasive Bladder Cancer (MIBC)

Pfizer

Astellas and Pfizer via the “Pfizer-Astellas Alliance” are collaborating to offer a new grant opportunity seeking proposals for independent medical education initiatives that bring awareness and knowledge to healthcare professionals regarding current medical education gaps in the locally advanced / metastatic urothelial cancer (la/mUC) and the rapidly evolving muscle invasive bladder cancer (MIBC) treatment landscapes. Therefore, grant applications with a focus on how emerging data could be practice changing for those who treat patients with bladder cancer are requested.

Ex-US multi-regional with priority given to Europe, Canada, China, Middle East, Russia, Turkey, Latin America, Asia-Pacific countries, Australia and Taiwan. US learners are not excluded but are not a priority geography.

Applications with educational content in multiple languages are well received.

Please note Astellas and Pfizer are unfortunately unable to accept applications from Japan, Italy and South-Korea, as per local law and regulation.

Project Types and Area of Interest As the treatment landscape for urothelial cancer is rapidly evolving, emerging data needs to be adopted quickly into clinical practice (e.g. Enfortumab Vedotin-based combinations). Potential applicants are encouraged to identify and address the educational needs for la/mUC and/or MIBCconsidering regional differences in treatment access, sequencing norms, and local guideline adoption. Projects for this competitive grant program will be considered for support if they focus on one or more of the following:

Locally advanced / metastatic urothelial carcinoma (la/mUC):

• Classification of the holistic treatment and care of patients with lA/mUC recommended in the guidelines, with a focus on first-line therapy, including but not limited to:

o Selection of eligible patients with la/mUC including patients underrepresented in clinical trials, e.g. very old, ECOG 2 and higher, mixed histologies, etc

o Selection and sequencing of therapies in la/mUC including combination regimes

o Antibody drug conjugate (ADC)-related adverse event (AE) management: education of patients and caregivers, importance of early identification and management of those AEs, value of dose modifications (holds and reductions) to keep patients on therapy for longer and improve treatment outcomes (objective response dynamics, partial response (PR) to complete response (CR) conversions)

• Understanding the evolving impact of novel combination regimens on earlier disease settings and impact on 1L therapeutic sequencing (MIBC to La/mUC)

Funding Range: Individual projects requests from US$10,000 - US$150,000 will be considered. The amount of any grant funded by Astellas and Pfizer for any educational activity may vary from the amount requested. Multi-support grant applications are preferred.

AI Based Application Success Predictor

Direct alignment with Pfizer’s therapeutic focus areas, such as:
- Oncology
- Vaccines
- Inflammation & Immunology
- Rare diseases
Projects addressing unmet medical needs are prioritized

👉 Misalignment with Pfizer’s current RFP (Request for Proposals) is a major rejection factor

🎯 2. Clear Impact on Patient Outcomes

Pfizer strongly favors proposals that demonstrate:

Improved patient care or clinical outcomes
Real-world applicability (not purely theoretical research)
Measurable endpoints (e.g., survival, quality of life, adherence)

👉 Compared to academic grants, practical impact is more heavily weighted

🧪 3. Robust Study Design & Methodology

Successful applications typically include:

Well-defined study protocols
Appropriate statistical plans
Feasible recruitment strategies

👉 Weak methodology is one of the most common rejection reasons

👩‍⚕️ 4. Investigator Credentials & Track Record

Proven publication record in the relevant field
Prior clinical research experience
Institutional support and infrastructure

👉 Early-career applicants can succeed, but usually with:

Strong mentorship
Clear feasibility

🏥 5. Institutional Capability

Access to:
- Patient population
- Clinical facilities
- Data management systems
Experience in conducting industry-sponsored trials

🤝 6. Independence & Transparency

For Pfizer grants (especially IIR):

Research must be investigator-initiated and independent
Clear disclosure of:
- Conflicts of interest
- Data ownership
Pfizer does not control study outcomes

💰 7. Realistic & Justified Budget

Budget must align with:
- Study scope
- Timeline
Overinflated or vague budgets reduce success chances

📑 8. Compliance with RFP Requirements

Strict adherence to:
- Proposal format
- Submission guidelines
- Required documentation

👉 Non-compliance can lead to automatic disqualification

🌍 9. Geographic & Strategic Priorities

Pfizer often prioritizes:
- Regions with high disease burden
- Projects aligned with global health strategies

⏳ 10. Feasibility & Timeline

Clearly achievable milestones
Realistic timelines
Defined deliverables

📊 Summary: Key Predictors (Ranked)

Highest impact factors:

Alignment with Pfizer RFP & therapeutic area
Patient-centered impact
Strong methodology

Moderate predictors:
4. Investigator track record
5. Institutional capability
6. Feasibility

Supporting factors:
7. Budget clarity
8. Compliance
9. Independence & transparency

💡 Insider Insight

Unlike Horizon Europe or NIH-type grants:

👉 Pfizer funding is more application-driven than theory-driven
👉 “Will this improve patient care soon?” is the central evaluation lens

Specialties

Cancer

Pharmaceuticals

Oncology

Urology

Eligibility Requirements

• The following organisations may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.

• Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).

• If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.

• The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead’s grant coordinator).

• The project/program lead must be an employee or contractor of the requesting organization.

• Requesting organization must be legally able to receive award funding directly from Astellas Pharma Global Development. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Astellas Pharma Global Development may be subject to rescission with any amounts already provided, required to be returned.

• For projects offering continuing education credit, the requesting organization must be accredited by a reputable accreditation body.

Sponsor Details

Sponsor Institute/Organizations: Pfizer

Sponsor Type: Corporate/Non-Profit

Address: 66 Hudson Boulevard East, New York, NY 10001

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity